サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1691875

ヒストプラスマ症治療の世界市場レポート 2025年

Histoplasmosis Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ヒストプラスマ症治療の世界市場レポート 2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒストプラスマ症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で77億4,000万米ドルに成長します。予測期間の成長は、遠隔医療と遠隔診察、患者教育とサポート、償還政策に起因しています。予測期間の主な動向には、抗真菌剤耐性管理、併用療法、免疫調節療法、高度診断ツールが含まれます。

慢性疾患の増加は、今後数年間のヒストプラスマ症治療市場の成長を牽引すると予想されます。慢性疾患は、3ヶ月以上持続し、時間の経過とともに悪化する可能性のある長期にわたる疾患です。ヒストプラスマ症治療は、呼吸器の健康を改善し、炎症を抑え、免疫系機能を強化し、慢性疾患を患う患者の生活の質を向上させます。例えば、2024年6月、オーストラリアの政府機関であるオーストラリア保健福祉研究所は、慢性疾患の年齢標準化死亡率が人口10万人当たり448人で、2021年には10万人当たり459人に上昇し、2022年には10万人当たり490人にさらに上昇すると報告しました。したがって、慢性疾患の罹患率の上昇がヒストプラスマ症治療市場の成長を牽引しています。

ヒト免疫不全ウイルス（HIV）の有病率の上昇は、当面のヒストプラスマ症治療市場拡大の大きな原動力になると予測されています。HIVは、CD4細胞（T細胞）を標的とし、感染症や病気と闘う免疫系の能力を弱めるウイルスであり、その流行はますます拡大しています。例えば、2023年7月現在、スイスに本部を置く国連機関である世界保健機関（WHO）によると、2022年に世界で報告されたHIV感染者数は3,900万人で、HIVに関連した死亡者数は63万人です。その結果、HIVの蔓延がヒストプラスマ症治療市場の成長を促進する要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界ヒストプラスマ症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界のヒストプラスマ症治療市場：成長率分析
  • 世界のヒストプラスマ症治療市場の実績：規模と成長, 2019-2024
  • 世界のヒストプラスマ症治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界ヒストプラスマ症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のヒストプラスマ症治療市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • アンホテリシンB
  • イトラコナゾール
  • ケトコナゾール
  • その他の薬剤の種類
  • 世界のヒストプラスマ症治療市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 注射可能
  • オーラル
  • その他の投与方法
  • 世界のヒストプラスマ症治療市場患者タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 小児科
  • 成人用
  • 世界のヒストプラスマ症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 個人クリニック
  • ドラッグストア
  • 小売薬局
  • eコマース
  • その他のエンドユーザー
  • 世界のヒストプラスマ症治療市場、アムホテリシンBのサブセグメンテーション、テストによる、実績と予測, 2019-2024, 2024-2029F, 2034F
  • リポソームアムホテリシンB
  • 従来のアムホテリシンB
  • 世界のヒストプラスマ症治療市場、イトラコナゾールのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • カプセル剤
  • 経口液剤
  • 世界のヒストプラスマ症治療市場ケトコナゾールのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 経口錠剤
  • 外用クリーム
  • 世界のヒストプラスマ症治療市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ポサコナゾール
  • ボリコナゾール

第7章 地域別・国別分析

  • 世界のヒストプラスマ症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のヒストプラスマ症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ヒストプラスマ症治療市場：競合情勢
  • ヒストプラスマ症治療市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Novartis AG
  • Sanofi S.A
  • Bristol Myers Squibb
  • AstraZeneca Plc
  • Abbott laboratories
  • GSK Plc
  • Eli Lilly and Company
  • Gilead Sciences
  • Teva Pharmaceutical Industries Ltd.
  • Astellas pharma US Inc.
  • Mylan N.V.
  • Biogen Inc.
  • Bausch Health Companies Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • AB Science

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ヒストプラスマ症治療市場2029：新たな機会を提供する国
  • ヒストプラスマ症治療市場2029：新たな機会を提供するセグメント
  • ヒストプラスマ症治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r28264

Histoplasmosis treatment encompasses a range of medical interventions and therapies aimed at combatting the fungal infection caused by the Histoplasma capsulatum fungus. This particular fungus is commonly found in soil, especially in areas where substantial accumulations of bird or bat droppings exist. The approach to treatment is tailored to factors such as the infection's severity, the overall health of the patient, and the presence of any underlying medical conditions.

Histoplasmosis treatment encompasses a range of medical interventions and therapies aimed at combatting the fungal infection caused by the Histoplasma capsulatum fungus. This particular fungus is commonly found in soil, especially in areas where substantial accumulations of bird or bat droppings exist. The approach to treatment is tailored to factors such as the infection's severity, the overall health of the patient, and the presence of any underlying medical conditions.

The histoplasmosis treatment market research report is one of a series of new reports from The Business Research Company that provides histoplasmosis treatment market statistics, including histoplasmosis treatment industry global market size, regional shares, competitors with a histoplasmosis treatment market share, detailed histoplasmosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the histoplasmosis treatment industry. This histoplasmosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The histoplasmosis treatment market size has grown strongly in recent years. It will grow from $5.13 billion in 2024 to $5.53 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to geographic prevalence, awareness and diagnosis, global health initiatives, research and drug development.

The histoplasmosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to telemedicine and remote consultations, patient education and support, reimbursement policies. Major trends in the forecast period include antifungal resistance management, combination therapies, immunomodulatory therapies, advanced diagnostic tools.

The increasing prevalence of chronic diseases is expected to drive the growth of the histoplasmosis treatment market in the coming years. Chronic diseases are long-lasting conditions that persist for three months or more and may worsen over time. Histoplasmosis treatment helps improve respiratory health, reduce inflammation, enhance immune system function, and improve the quality of life for patients suffering from chronic diseases. For example, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that the age-standardized death rate for chronic conditions was 448 per 100,000 population, rising to 459 per 100,000 in 2021 and further increasing to 490 per 100,000 in 2022. Therefore, the rising incidence of chronic diseases is driving the growth of the histoplasmosis treatment market.

The escalating prevalence of human immunodeficiency virus (HIV) is projected to be a major driving force behind the expansion of the histoplasmosis treatment market in the foreseeable future. HIV, a virus that targets CD4 cells (T cells) and weakens the immune system's ability to combat infections and diseases, has become increasingly prevalent. Histoplasmosis treatment plays a vital role in managing the fungal infection for AIDS patients, aiding in the prevention of disseminated disease and reducing mortality through the use of antifungal medications like itraconazole or amphotericin B. For instance, as of July 2023, according to the World Health Organization, a Switzerland-based United Nations agency, there were 39 million reported cases of HIV globally in 2022, resulting in 630,000 deaths from HIV-related causes. Consequently, the mounting prevalence of HIV is a key driver in the growth of the histoplasmosis treatment market.

Key players in the histoplasmosis treatment market are pioneering inventive approaches to fortify their market presence. Breakthroughs in antifungal drug research have paved the way for novel compounds and strategies specifically designed to combat invasive histoplasmosis. For instance, in June 2022, Apex Laboratories, an India-based pharmaceutical company, unveiled an advanced iteration of Itraconazole Capsules Supra Bioavailable in 65 and 130 mg variants-a potent therapeutic option for effectively managing fungal infections. These capsules deliver a remarkable 90% of active medicine to the biological system at a reduced dosage, catering to a range of fungal infections like blastomycosis, histoplasmosis, and aspergillosis. Their creation involves cutting-edge spray granulation technology, which accelerates the dissolution rate of itraconazole. This medication is uniformly present in solid dispersion, sans pellets. Such innovative techniques enhance the bioavailability of medications with low solubility.

Major companies operating in the histoplasmosis treatment market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol Myers Squibb, AstraZeneca PLC, Abbott laboratories, GSK PLC, Eli Lilly and Company, Gilead Sciences, Teva Pharmaceutical Industries Ltd., Astellas pharma US Inc., Mylan N.V., Biogen Inc., Bausch Health Companies Inc., Mitsubishi Tanabe Pharma Corporation, AB Science, Ionis Pharmaceuticals Inc., Advanz Pharma Corp., Leadiant Biosciences, IMMY, Sigma Tau Pharmaceuticals Inc.

North America was the largest region in the histoplasmosis treatment market in 2024. The regions covered in histoplasmosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the histoplasmosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The histoplasmosis treatment consists of sales of antifungal medications and posaconazole. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Histoplasmosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on histoplasmosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for histoplasmosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The histoplasmosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Type: Amphotericin B; Itraconazole; Ketoconazole; Other Drug Type
  • 2) By Mode of Administration: Injectable; Oral; Other Mode Of Administration
  • 3) By Patient Type: Pediatric; Adult
  • 4) By End-User: Hospital Pharmacies; Private Clinics; Drug Stores; Retail Pharmacies; E-Commerce; Other End-Users
  • Subsegments:
  • 1) By Amphotericin B: Liposomal Amphotericin B; Conventional Amphotericin B
  • 2) By Itraconazole: Capsule Form; Oral Solution
  • 3) By Ketoconazole: Oral Tablets; Topical Creams
  • 4) By Other Drug Type: Posaconazole; Voriconazole
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Histoplasmosis Treatment Market Characteristics

3. Histoplasmosis Treatment Market Trends And Strategies

4. Histoplasmosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Histoplasmosis Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Histoplasmosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Histoplasmosis Treatment Market Growth Rate Analysis
  • 5.4. Global Histoplasmosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Histoplasmosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Histoplasmosis Treatment Total Addressable Market (TAM)

6. Histoplasmosis Treatment Market Segmentation

  • 6.1. Global Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amphotericin B
  • Itraconazole
  • Ketoconazole
  • Other Drug Type
  • 6.2. Global Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Injectable
  • Oral
  • Other Mode Of Administration
  • 6.3. Global Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric
  • Adult
  • 6.4. Global Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce
  • Other End-Users
  • 6.5. Global Histoplasmosis Treatment Market, Sub-Segmentation Of Amphotericin B, By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liposomal Amphotericin B
  • Conventional Amphotericin B
  • 6.6. Global Histoplasmosis Treatment Market, Sub-Segmentation Of Itraconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Capsule Form
  • Oral Solution
  • 6.7. Global Histoplasmosis Treatment Market, Sub-Segmentation Of Ketoconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Tablets
  • Topical Creams
  • 6.8. Global Histoplasmosis Treatment Market, Sub-Segmentation Of Other Drug Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Posaconazole
  • Voriconazole

7. Histoplasmosis Treatment Market Regional And Country Analysis

  • 7.1. Global Histoplasmosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Histoplasmosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Histoplasmosis Treatment Market

  • 8.1. Asia-Pacific Histoplasmosis Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Histoplasmosis Treatment Market

  • 9.1. China Histoplasmosis Treatment Market Overview
  • 9.2. China Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Histoplasmosis Treatment Market

  • 10.1. India Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Histoplasmosis Treatment Market

  • 11.1. Japan Histoplasmosis Treatment Market Overview
  • 11.2. Japan Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Histoplasmosis Treatment Market

  • 12.1. Australia Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Histoplasmosis Treatment Market

  • 13.1. Indonesia Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Histoplasmosis Treatment Market

  • 14.1. South Korea Histoplasmosis Treatment Market Overview
  • 14.2. South Korea Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Histoplasmosis Treatment Market

  • 15.1. Western Europe Histoplasmosis Treatment Market Overview
  • 15.2. Western Europe Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Histoplasmosis Treatment Market

  • 16.1. UK Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Histoplasmosis Treatment Market

  • 17.1. Germany Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Histoplasmosis Treatment Market

  • 18.1. France Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Histoplasmosis Treatment Market

  • 19.1. Italy Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Histoplasmosis Treatment Market

  • 20.1. Spain Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Histoplasmosis Treatment Market

  • 21.1. Eastern Europe Histoplasmosis Treatment Market Overview
  • 21.2. Eastern Europe Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Histoplasmosis Treatment Market

  • 22.1. Russia Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Histoplasmosis Treatment Market

  • 23.1. North America Histoplasmosis Treatment Market Overview
  • 23.2. North America Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Histoplasmosis Treatment Market

  • 24.1. USA Histoplasmosis Treatment Market Overview
  • 24.2. USA Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Histoplasmosis Treatment Market

  • 25.1. Canada Histoplasmosis Treatment Market Overview
  • 25.2. Canada Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Histoplasmosis Treatment Market

  • 26.1. South America Histoplasmosis Treatment Market Overview
  • 26.2. South America Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Histoplasmosis Treatment Market

  • 27.1. Brazil Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Histoplasmosis Treatment Market

  • 28.1. Middle East Histoplasmosis Treatment Market Overview
  • 28.2. Middle East Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Histoplasmosis Treatment Market

  • 29.1. Africa Histoplasmosis Treatment Market Overview
  • 29.2. Africa Histoplasmosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Histoplasmosis Treatment Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Histoplasmosis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Histoplasmosis Treatment Market Competitive Landscape
  • 30.2. Histoplasmosis Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Histoplasmosis Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A
  • 31.3. Bristol Myers Squibb
  • 31.4. AstraZeneca Plc
  • 31.5. Abbott laboratories
  • 31.6. GSK Plc
  • 31.7. Eli Lilly and Company
  • 31.8. Gilead Sciences
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Astellas pharma US Inc.
  • 31.11. Mylan N.V.
  • 31.12. Biogen Inc.
  • 31.13. Bausch Health Companies Inc.
  • 31.14. Mitsubishi Tanabe Pharma Corporation
  • 31.15. AB Science

32. Global Histoplasmosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Histoplasmosis Treatment Market

34. Recent Developments In The Histoplasmosis Treatment Market

35. Histoplasmosis Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Histoplasmosis Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Histoplasmosis Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Histoplasmosis Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer